 |
|
anti-CD19-DM4 immunoconjugate SAR3419
An immunoconjugate consisting of an anti-CD19 monoclonal antibody conjugated to the maytansinoid DM4, a derivative of the cytotoxic agent maytansine (DM1), with potential antineoplastic activity. Anti-CD19-DM4 conjugate SAR3419 targets the cell surface antigen CD19, found on a number of B-cell-derived cancers. Upon antibody/antigen binding and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in inhibition of cell division and cell growth of CD19-expressing tumor cells.
Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Code name: | | SAR3419 | | |
| Previous: | anti-1-amino-3-[18F ]fluorocyclobutane-1-carboxylic acid, anti-B4 blocked ricin immunotoxin, anti-CCL-2 human monoclonal antibody CNTO 888, anti-CD137 monoclonal antibody, anti-CD19 fully human monoclonal antibody MDX-1342 | | Next: | anti-CD20 monoclonal antibody AME-133v, anti-CD20 monoclonal antibody R7159, anti-CD200 monoclonal antibody ALXN6000, anti-CD22 immunotoxin CAT-8015, anti-CD3 immunotoxin A-dmDT390-bisFv(UCHT1) |
|
|
